Mechanistically, tumor-derived MIF competitively inhibits CXCL12-CXCR4 binding—a canonical pathway essential for GC B cell affinity maturation 35—thereby impairing antibody-driven immunity (Figure 6F). The gene discussed is CXCL12; the disease is neoplasm.